Novo chief on approval of prize asset: Probably the biggest achievement

The approval of Novo Nordisk’s GLP-1 analogue Ozempic is probably “the biggest” achievement for chief science officer (CSO) Mads Krogsgaard Thomsen during his 26 years in the Danish diabetes group. He is happy that the company now possesses the two best products of the drug class.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Latest Top picks in English

Related articles